← All organizations
Highest phase reached
Phase 3
First clinical trial
Nov 1, 2008First marketed drug
Feb 6, 2019First NDA
Feb 6, 2019Last known activity
Jun 30, 2018
Acquired by Sanofi-Aventis on Jan 29, 2018
Timeline
2000s
- Nov 1, 2001
Ablynx— Founded
2010s
- Jan 29, 2018
Sanofi-Aventis— Acquired By
- Feb 6, 2019
caplacizumab— Marketing Organization
- Feb 6, 2019
caplacizumab— NDA Organization
Drugs by trial phase (9 distinct, 25 trials)
Phase 3 (1 own, 0 via acquisition)
Phase 2 (6 own, 0 via acquisition)
Phase 1 (2 own, 0 via acquisition)
Indications
Studied for
- Angina Pectoris
- Angina, Stable
- Angina, Unstable
- Arthritis
- Arthritis, Rheumatoid
- Communicable Diseases
- Infarction
- Infections
- Lupus Erythematosus, Systemic
- Myocardial Infarction
- Purpura
- Purpura, Thrombocytopenic
- Purpura, Thrombotic Thrombocytopenic
- Respiratory Syncytial Virus Infections
- Respiratory Tract Infections
- Virus Diseases
Marketed drugs (1)
Recent trials (50)
- NCT03468829Lead sponsorPhase 2Jun 30, 2018
- NCT03468829Study directorPhase 2Jun 30, 2018
- NCT03418571Study directorPhase 2Mar 1, 2018
- NCT03418571Lead sponsorPhase 2Mar 1, 2018
- NCT03172208Lead sponsorPhase 1Jun 1, 2017
- NCT03172208Study directorPhase 1Jun 1, 2017
- NCT02979431Study directorPhase 2Dec 1, 2016
- NCT02979431Lead sponsorPhase 2Dec 1, 2016
- NCT02878603Lead sponsorPhase 3Aug 1, 2016
- NCT02878603Study directorPhase 3Aug 1, 2016
- NCT02553317Lead sponsorPhase 3Sep 1, 2015
- NCT02553317Study directorPhase 3Sep 1, 2015
- NCT02518620Study directorPhase 2Jul 1, 2015
- NCT02437890Lead sponsorPhase 2Jul 1, 2015
- NCT02437890Study directorPhase 2Jul 1, 2015
Details
- Founded
- Ghent, BE Nov 1, 2001
- First NDA
- Feb 6, 2019
- Last known activity
- Jun 30, 2018
Designations held
- Orphan drug
- Fast track
- Priority review